Literature DB >> 20357097

Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys.

Wendy W Yeh1, Ishita Rahman, Peter Hraber, Rory T Coffey, Daiva Nevidomskyte, Ayush Giri, Mohammed Asmal, Svetlana Miljkovic, Marcus Daniels, James B Whitney, Brandon F Keele, Beatrice H Hahn, Bette T Korber, George M Shaw, Michael S Seaman, Norman L Letvin.   

Abstract

While the simian immunodeficiency virus (SIV)-infected rhesus monkey is an important animal model for human immunodeficiency virus type 1 (HIV-1) infection of humans, much remains to be learned about the evolution of the humoral immune response in this model. In HIV-1 infection, autologous neutralizing antibodies emerge 2 to 3 months after infection. However, the ontogeny of the SIV-specific neutralizing antibody response in mucosally infected animals has not been defined. We characterized the kinetics of the autologous neutralizing antibody response to the transmitted/founder SIVmac251 using a pseudovirion-based TZM-bl cell assay and monitored env sequence evolution using single-genome amplification in four rhesus animals that were infected via intrarectal inoculations. We show that the SIVmac251 founder viruses induced neutralizing antibodies at 5 to 8 months after infection. Despite their slow emergence and low titers, these neutralizing antibodies selected for escape mutants that harbored substitutions and deletions in variable region 1 (V1), V2, and V4 of Env. The neutralizing antibody response was initially focused on V4 at 5 to 8 months after infection and then targeted V1/V2 and V4 by 16 months. These findings reveal a striking delay in the development of neutralizing antibodies in SIVmac-infected animals, thus raising questions concerning the suitability of SIVmac251 as a challenge strain to screen AIDS vaccines that elicit neutralizing antibodies as a means to prevent virus acquisition. They also illustrate the capacity of the SIVmac quasispecies to modify antigenic determinants in response to very modest titers of neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20357097      PMCID: PMC2876635          DOI: 10.1128/JVI.02741-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  76 in total

1.  Datamonkey: rapid detection of selective pressure on individual sites of codon alignments.

Authors:  Sergei L Kosakovsky Pond; Simon D W Frost
Journal:  Bioinformatics       Date:  2005-02-15       Impact factor: 6.937

2.  Not so different after all: a comparison of methods for detecting amino acid sites under selection.

Authors:  Sergei L Kosakovsky Pond; Simon D W Frost
Journal:  Mol Biol Evol       Date:  2005-02-09       Impact factor: 16.240

3.  The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.

Authors:  Cheryl J Saunders; Ruth A McCaffrey; Irina Zharkikh; Zane Kraft; Susan E Malenbaum; Brian Burke; Cecilia Cheng-Mayer; Leonidas Stamatatos
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection.

Authors:  Simon D W Frost; Terri Wrin; Davey M Smith; Sergei L Kosakovsky Pond; Yang Liu; Ellen Paxinos; Colombe Chappey; Justin Galovich; Jeff Beauchaine; Christos J Petropoulos; Susan J Little; Douglas D Richman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-09       Impact factor: 11.205

5.  An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.

Authors:  L Stamatatos; C Cheng-Mayer
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

6.  Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies.

Authors:  Sang-Moo Kang; Fu Shi Quan; Chunzi Huang; Lizheng Guo; Ling Ye; Chinglai Yang; Richard W Compans
Journal:  Virology       Date:  2005-01-05       Impact factor: 3.616

7.  Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels.

Authors:  Bhavna Chohan; Dorothy Lang; Manish Sagar; Bette Korber; Ludo Lavreys; Barbra Richardson; Julie Overbaugh
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

8.  Changes in the extracellular envelope glycoprotein of variants that evolve during the course of simian immunodeficiency virus SIVMne infection affect neutralizing antibody recognition, syncytium formation, and macrophage tropism but not replication, cytopathicity, or CCR-5 coreceptor recognition.

Authors:  L M Rudensey; J T Kimata; E M Long; B Chackerian; J Overbaugh
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

9.  Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque.

Authors:  J Glamann; D R Burton; P W Parren; H J Ditzel; K A Kent; C Arnold; D Montefiori; V M Hirsch
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

10.  Structure of an unliganded simian immunodeficiency virus gp120 core.

Authors:  Bing Chen; Erik M Vogan; Haiyun Gong; John J Skehel; Don C Wiley; Stephen C Harrison
Journal:  Nature       Date:  2005-02-24       Impact factor: 49.962

View more
  23 in total

1.  Primary infection by a human immunodeficiency virus with atypical coreceptor tropism.

Authors:  Chunlai Jiang; Nicholas F Parrish; Craig B Wilen; Hui Li; Yue Chen; Jeffrey W Pavlicek; Anna Berg; Xiaozhi Lu; Hongshuo Song; John C Tilton; Jennifer M Pfaff; Elizabeth A Henning; Julie M Decker; M Anthony Moody; Mark S Drinker; Robert Schutte; Stephanie Freel; Georgia D Tomaras; Rebecca Nedellec; Donald E Mosier; Barton F Haynes; George M Shaw; Beatrice H Hahn; Robert W Doms; Feng Gao
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

2.  Depletion of CD4⁺ T cells abrogates post-peak decline of viremia in SIV-infected rhesus macaques.

Authors:  Alexandra M Ortiz; Nichole R Klatt; Bing Li; Yanjie Yi; Brian Tabb; Xing Pei Hao; Lawrence Sternberg; Benton Lawson; Paul M Carnathan; Elizabeth M Cramer; Jessica C Engram; Dawn M Little; Elena Ryzhova; Francisco Gonzalez-Scarano; Mirko Paiardini; Aftab A Ansari; Sarah Ratcliffe; James G Else; Jason M Brenchley; Ronald G Collman; Jacob D Estes; Cynthia A Derdeyn; Guido Silvestri
Journal:  J Clin Invest       Date:  2011-10-17       Impact factor: 14.808

3.  Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys.

Authors:  Wendy W Yeh; Laura M Brassard; Caroline A Miller; Aravind Basavapathruni; Jinrong Zhang; Srinivas S Rao; Gary J Nabel; John R Mascola; Norman L Letvin; Michael S Seaman
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

4.  Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.

Authors:  John B Schell; Nina F Rose; Kapil Bahl; Kathryn Diller; Linda Buonocore; Meredith Hunter; Preston A Marx; Ratish Gambhira; Haili Tang; David C Montefiori; Welkin E Johnson; John K Rose
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

5.  Persistence of SIV in the brain of SIV-infected Chinese rhesus macaques with or without antiretroviral therapy.

Authors:  Stefanie Perez; Ann-Marie Johnson; Shi-Hua Xiang; Jian Li; Brian T Foley; Lara Doyle-Meyers; Antonito Panganiban; Amitinder Kaur; Ronald S Veazey; Yuntao Wu; Binhua Ling
Journal:  J Neurovirol       Date:  2017-11-27       Impact factor: 2.643

6.  High cell-free virus load and robust autologous humoral immune responses in breast milk of simian immunodeficiency virus-infected african green monkeys.

Authors:  Andrew B Wilks; James R Perry; Elizabeth P Ehlinger; Roland C Zahn; Robert White; Marie-Claire Gauduin; Angela Carville; Michael S Seaman; Joern E Schmitz; Sallie R Permar
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

7.  Immunoglobulin VH gene diversity and somatic hypermutation during SIV infection of rhesus macaques.

Authors:  Kejun Guo; Kalani Halemano; Kimberly Schmitt; Miki Katuwal; Yaqiong Wang; Michael S Harper; Karl J Heilman; Takeo Kuwata; Edward B Stephens; Mario L Santiago
Journal:  Immunogenetics       Date:  2015-05-21       Impact factor: 2.846

8.  SIV infection duration largely determines broadening of neutralizing antibody response in macaques.

Authors:  Fan Wu; Ilnour Ourmanov; Andrea Kirmaier; Sivan Leviyang; Celia LaBranche; Jinghe Huang; Sonya Whitted; Kenta Matsuda; David Montefiori; Vanessa M Hirsch
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

9.  Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses.

Authors:  Mohammed Asmal; Yue Sun; Sophie Lane; Wendy Yeh; Stephen D Schmidt; John R Mascola; Norman L Letvin
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

10.  Rapid, complex adaptation of transmitted HIV-1 full-length genomes in subtype C-infected individuals with differing disease progression.

Authors:  Melissa-Rose Abrahams; Florette K Treurnicht; Nobubelo K Ngandu; Sarah A Goodier; Jinny C Marais; Helba Bredell; Ruwayhida Thebus; Debra de Assis Rosa; Koleka Mlisana; Cathal Seoighe; Salim Abdool Karim; Clive M Gray; Carolyn Williamson
Journal:  AIDS       Date:  2013-02-20       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.